ReviewArchives of microbiology2026
Advances in erythritol production through synthetic biology and systems metabolic engineering.
Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Synthetic biology has delivered a toolkit for erythritol production, yet a metabolic trade-off persists: strict dependence on pentose phosphate flux and NADPH regeneration pits product synthesis against cell growth and stress adaptation, rendering most engineering interventions unable to break the yield-productivity trade-off. This Review frames erythritol biomanufacturing within a hierarchical constraint cascade, tracing the progression from native strain optimization through synthetic biology-driven pathway rewiring, cofactor balancing, modular design, to AI-integrated design-build-test-learn (DBTL) cycles. Carbon precursor supply sets the flux ceiling, cofactor availability modulates conversion, and scale-dependent heterogeneities in mixing and feedstocks widen the gap between laboratory design and industrial operation. Comparison with other rare sugars (allulose, tagatose) reveals erythritol's unique challenges: deep pathway embedding and high reducing-power demand. While accelerating enzyme engineering, metabolic modelling and process control, current AI applications are most likely to succeed when coupled with mechanism-based, cross-scale models, rather than merely statistical fits. The next breakthrough lies in closing the loop between real-time sensing and adaptive flux regulation. This vision could be realized through integrated biomanufacturing platforms that combine mechanistic modeling, automated DBTL cycles, and cell-free systems where cellular constraints prove limiting. This Review offers a unified, scale-spanning framework for diagnosing systemic bottlenecks in erythritol biosynthesis and outlines principles for intelligent biomanufacturing of sugar alcohols.
Indexed as
Identifiers
42766016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.